**Dactinomycin**  

**Indication**: Malignant trophoblastic neoplasms of placenta  

**INN**: Dactinomycin  

**Medicine type**: Chemical agent  

**List type**: Complementary  

**Formulations**: Parenteral > General injections > IV: 500 µg in vial powder for injection  

**EML status history**: First added in 1984 (TRS 722)  

**Age**: Adolescents and adults  

**Sex**: All  

**Therapeutic alternatives**: The recommendation is for this specific medicine  

**Patent information**: Patents have expired in most jurisdictions  

**Tags**: Cancer  

**Wikipedia**: Dactinomycin  

**DrugBank**: Dactinomycin  

**Summary of evidence and Expert Committee recommendations**

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for dactinomycin on the complementary list of the EML for use in treatment protocols for gestational trophoblastic neoplasia was specifically endorsed. The relevant extracts from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for gestational trophoblastic neoplasia is attached.